title: LAPTM4B down regulation inhibits the proliferation, invasion and angiogenesis of HeLa cells in vitro.
abstract: OBJECTIVE
  LAPTM4B (lysosome-associated protein transmembrane 4 beta) is a novel oncogene with important functions in aggressive human carcinomas, including cervical cancer. However, the specific functions and internal molecular mechanisms associated with this gene in the context of cervical cancer remain unclear.
  
  
  METHODS
  In this study, we explored the effects and mechanisms of LAPTM4B on tumor growth, metastasis and angiogenesis in vitro by depletion of LAPTM4B in Hela cell. RNA interference was used to induce down regulation of LAPTM4B gene expression in Hela cells. The motility, migration potential, and proliferation of the Hela cells were measured by flow cytometry, Transwell migration assays, wound healing assays, and Cell Counting Kit-8 assays. In addition, the cell cycle analysis utilized fluorescence-activated cell sorting.
  
  
  RESULTS
  In this study, RNAi-mediated LAPTM4B knockdown inhibited cell growth and angiogenesis. In vitro, HeLa cells with down regulated LAPTM4B also exhibited decreased migration and invasion activity as well as significantly reduced CDK12, HIF-1α, MMP-2, MMP-9 and VEGF expression. LAPTM4B blockade significantly decreased cord lengths and branch points in a tube formation assay.
  
  
  CONCLUSIONS
  These results suggested that LAPTM4B inactivation could be a novel therapeutic target for cervical cancer.
authors.affiliation: Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China.
authors.forename: Fanling
authors.initials: F
authors.lastname: Meng
authors.forename: Xiuwei
authors.initials: X
authors.lastname: Chen
authors.forename: Hongtao
authors.initials: H
authors.lastname: Song
authors.forename: Ge
authors.initials: G
authors.lastname: Lou
mesh_terms: D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006367:HeLa Cells; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics / Q000378:metabolism; D066298:In Vitro Techniques; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000235:genetics* / Q000378:metabolism*; D015513:Oncogene Proteins / Q000235:genetics* / Q000378:metabolism*; D034622:RNA Interference; D015398:Signal Transduction; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
chemical_list: C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; C477083:LAPTM4B protein, human; D008565:Membrane Proteins; D015513:Oncogene Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A